Pay in 4 interest-free payments of $24.75 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
DeLucas LJ
Dominguez E
Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects
is a potent and selective antagonist for the prostaglandin E2 receptor subtype EP2
the compounds library sets are easy for you to purchase
THZ1 - Covalent CDK7 Inhibitor. CAS# 1604810-83-4 284 DeLucas LJTHZ1, CAS No. 1604810 83 4, is a novel potent, selective and cell permeable irreversible CDK7 inhibitor with an IC50 ~3. 2 nM. THZ1 has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. Cancer cell line profiling indicates that a subset of cancer cell lines, including human T cell acute lymphoblastic leukaemia (T ALL), have
US$ 66.00
US$ 1120.00
US$ 100.00
US$ 79.00
US$ 110.00
US$ 1000.00
US$ 123.00